Market revenue in 2023 | USD 14.8 million |
Market revenue in 2030 | USD 50.2 million |
Growth rate | 19% (CAGR from 2023 to 2030) |
Largest segment | Cell & gene therapy |
Fastest growing segment | Cell & Gene Therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cell & Gene Therapy, Immunotherapy |
Key market players worldwide | Charles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna contract manufacturing market will help companies and investors design strategic landscapes.
Cell & gene therapy was the largest segment with a revenue share of 60.81% in 2023. Horizon Databook has segmented the Germany plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
The increasing number of patients opting for gene therapy and rising demand for pDNA in various medical therapies drive growth of the market in the country. The country has sufficient funding for R&D, and its output of academic papers and patents is comparable to that of the world's top gene therapy countries, despite lagging in funding & development of clinical trials & commercialized gene therapies as compared to other countries.
Moreover, use of advanced technology by pharmaceutical & biopharmaceutical companies expedites the development of CGTs, which would increase the popularity of gene therapies. For instance, in 2020, Merck, a leading scientific and technology company, launched its VirusExpress Lentiviral Production platform to produce viral vectors.
Thus, manufacturers adopting the platform enhances the production & manufacturing of gene therapies, which would also drive the demand for the pDNA contract manufacturing market due to quicker approval & less time consumed in developing therapies.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany plasmid dna contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Germany plasmid dna contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account